Robert Talac: Is PRP Truly Autologous?
Robert Talac, Medical Director at Renaxis Regenerative Orthopedic Center, shared a post on LinkedIn:
“PRP Is Not Fully Autologous.
We should probably talk about that.
I’ve been in regenerative medicine for over 30 years.
For most of that time, PRP was widely accepted as the gold standard of autologous biologics.
I want to challenge that.
Here’s what’s actually in a standard PRP preparation:
- Citrate or EDTA anticoagulants (not from the patient)
- Bovine thrombin as an activator (not from thepatient)
- Calcium chloride to trigger clotting (not from the patient)
None of these are autologous. And it’s not a minor footnote.
EDTA and citrate disturb natural ionic homeostasis and alter cytokine profiles.
Bovine thrombin carries a documented immunogenicity risk, potentially triggering antibody responses against the patient’s own clotting factors.
This is not a fringe concern. It’s in the published data.
Platelet-Rich Fibrin (PRF), by contrast, uses no anticoagulant.
- Blood is drawn and immediately centrifuged.
- Clotting occurs through physiologic thrombin alone.
- No external activator, no foreign additive, no biochemical modification.
One caveat worth naming: many commercial PRF kits use silica or silicone-coated tubes as clot activators.
Those are foreign materials, too.
Which is why I use plain glass tubes (Bio-PRF) – the only truly additive-free option.
The result?
A dense autologous platelet-rich fibrin matrix. Nothing added. Nothing altered.
We’ve spent decades debating PRP activation protocols, platelet concentrations, and leucocyte ratios. Maybe the more important question is simpler:
If autologous therapy is the goal – is PRP actually”
Stay updated with Hemostasis Today.
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
-
Jun 28, 2026, 09:41Sung-mok Jung: How Environmental Drivers Influence SFTS Occurrence
-
Jun 28, 2026, 05:17Burcu Tunakan: Turning Collaboration into Better Outcomes for People with Hemophilia
-
Jun 28, 2026, 05:08Kathrine Kaspersen: The Power of Voluntary Plasma Donation
-
Jun 28, 2026, 04:55Sana Helani: Challenging Common Assumptions in Anemia Management
-
Jun 28, 2026, 04:55Samwel Mikaye: The Collapse of Coagulation Control in Disseminated Intravascular Coagulation